Abstract
The effects of the 5-HT 1A/1B/1D/5/7 receptor agonist, 5-carboxamidotryptamine (5-CT), on blood glucose, insulin and glucagon levels in rats were investigated. 5-CT above the dosage of 0.05 mg/kg elicited significant hyperglycemic effects and 0.1 mg/kg, induced a 35% increase in plasma glucose levels. 5-CT did not affect plasma glucagon, and serum insulin levels increased following the high dose of 5-CT. Adrenodemedullation abolished the 5-CT-induced hyperglycemia. Hyperglycemia induced by 5-CT was prevented by pretreatment with the 5-HT 1/2/7 receptor antagonist, metergoline, and the 5-HT 1/2/5/7 receptor antagonist, methysergide, although the 5-HT 2A receptor antagonist, ketanserin, the 5-HT 2A/2B/2C receptor antagonist, ritanserin, and the 5-HT 3/4 receptor antagonist, tropisetron, had no effect. Although 5-CT has a high affinity with 5-HT 1A receptors, the 5-HT 1A and 5-HT 1B and β receptor antagonist, (−)-popranolol, did not affect 5-CT-induced hyperglycemia. These results indicate that 5-CT-induced hyperglycemia is elicited by facilitation of adrenaline release from the adrenal gland and that 5-CT-induced hyperglycemia is mediated by the 5-HT 7 receptor unrelated to 5-HT 1A, 5-HT 1B, 5-HT 2, 5-HT 3, 5-HT 4 or 5-HT 5 receptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
